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Treatment of children with acute lymphoblastic leukaemia (ALL) and non-Hodgkin's lymphoma has become more intensive and more successful in recent years. The first few months from diagnosis are punctuated by repeated admissions to hospital for periods of intensive chemotherapy, and often by readmission for management of the resulting fever and neutropenia. However, over half of the treatment period for virtually all children with ALL and for many with non-Hodgkin's lymphoma of T cell subtype is spent receiving oral drugs as an outpatient and during this phase of 'maintenance' treatment shared care between the tertiary centre and the local paediatric unit comes into its own.
How often should children have blood counts during maintenance treatment? What is the risk of infections and how should they be managed? What is the risk of chickenpox or measles? What advice should be given at the time of stopping treatment? These are some of the many questions asked by parents, paediatricians, and family doctors. In this article the author reviews her approach to these problems which arise during maintenance or continuing treatment. with both mercaptopurine and steroids has been documented. '9 20 .t is Planning continuing (maintenance)
)to-chemotherapy ares Parents are bombarded with facts at the time of diagnosis of childhood leukaemia and it is important to recognise that all information given at the time of diagnosis needs to be repeated and reinforced. A natural time to disd to cuss continuing treatment in detail is after lites completion of central nervous system directed lren treatment, whether this has comprised cranial pto-irradiation, intravenous methotrexate, or a )me course of weekly intrathecal methotrexate ong injections. At this stage it is worth spending ner-time with parents and patients if appropriate able going through the continuing treatment iex-diagram (figure), stressing the importance of the adequate drug doses and adjustments accordstay ing to the blood count. A comparison can be ,it it drawn with adjustments of insulin dose made line in childhood diabetes. It is our practice in the clinic to give parents the follow up forms, TLL together with a booklet we have prepared n of about continuing chemotherapy, which conther tains instructions on completion of the forms, iilar details about drug dose adjustment, and appendices containing tables of the appropriate full and reduced doses of drugs according to surface area and the number of tablets needed to provide appropriate doses of drugs. vin-Most parents are anxious to learn and to are contribute as much as possible to treatment and and, provided the booklet and instructions are ned also sent to the shared care centre, this system of seems to work well. Drugs are started at the The recommended top dose based on surface area the and parents are warned that this is merely an and empirical start dose, that the right dose is the [city maximum one tolerated by the individual ove patient, that one or more episodes of neutropenia are inevitable and do not herald relapse of leukaemia.
It is important to ensure a follow up discussion, usually at the shared care centre to make mes sure that these points have been understood.
Leu-Calculation of surface area every three months co-provides an opportunity for reviewing the drug rally dose during the preceding cycle and ensures lrug that the height is regularly recorded to facilitate the updating of the growth chart, which should be the maintained in every child receiving chemotherapy. This regular review of drug doses is essential throughout treatment and, unfortunately, blood counts are essential every one to two weeks to ensure that children receive the maximum tolerated dose of drugs. There is no reason to keep children off school, away from playgroup, or even worse in hospital if they are neutropenic during continuing treatment. The drugs used in continuing treatment do not cause acute gut toxicity and thus fever in association with neutropenia is rare, and will not be prevented by social isolation.
Children who are never neutropenic There are some children who, while prescribed maximum drug doses according to protocol, or even higher doses, never become neutropenic. It is very important to check that there is no misunderstanding about giving the drugs. There is evidence that poor compliance may be a factor here and it is important to consider this, and perhaps measure thiopurine metabolites. Boys tolerate higher doses of mercaptopurine than girls and become neutropenic less readily; this may be a factor in their higher relapse rate.12 It is important to increase the dose of 6-mercaptopurine consistently until the leucocyte count drops.
Infections during continuing (maintenance) treatment
The greatest cause of anxiety, and of telephone calls to the clinic, is the concern about serious infections during treatment and without active support and encouragement to do otherwise there is a real danger of children missing school or playgroup. There is no doubt that continuing treatment is immunosuppressive, and tragically up to 5% of children may die from intercurrent infection during treatment. 23 However, many of these deaths are avoidable, and are due to a limited number of infections discussed below. There is little evidence that children with ALL are more likely to get common mild viral infections than other children, and, with the exceptions mentioned below, any intercurrent infections should be managed in the normal way. Bone marrows and lumbar punctures Routine bone marrows during and after stopping treatment do not influence prognosis and have been abandoned in most clinics including ours. It is, however, conceivable that the facility to monitor minimal residual disease may lead to reintroduction of marrows at some stages during treatment. By contrast, now that cranial irradiation has been abandoned for many children the majority now have regular lumbar punctures during treatment. It is important that central nervous system relapse is well documented as reactive mononuclear cells are common during regular intrathecal chemotherapy and these can be extremely difficult to differentiate from leukaemic blast cells.
MEASLES
Immunisation policy Live vaccines should not be given during treatment. They are not effective and may prove harmful. We recommend that children are revaccinated at six months after stopping treatment with diphtheria, polio, and tetanus vaccines. If a child was fully immunised before diagnosis of leukaemia then only boosters are indicated. Measles, mumps, and rubella vaccine is given one year from completion of treatment. Full immunisation should be given to siblings and close friends; the only difference in the standard policy is that killed polio is recommended rather than live vaccines because of the risk of transmission of attenuated vaccine.
Stopping treatment
Stopping treatment is an extremely stressful time for families. Although the routine of treatment is burdensome there is a feeling that the treatment has kept the child well and the prospect of stopping the treatment reawakens all the natural anxieties about the future. It is important to recognise this and to give parents time for questions and discussion, backed up by an appointment at the tertiary centre.
We have found that giving parents a leaflet one to two months before the projected time of stopping, acts as a reminder for questions or problems. It is important to explain to the child that, although treatment is now stopping, follow up with blood counts and physical examinations will continue and that there can be no promises that treatment may not Relapse may be suspected on routine blood count, which we recommend is performed monthly for at least 18 months after stopping treatment, increasing the time interval thereafter. The testis remains an important site of relapse in boys and any untoward swelling of the testis should be reported and biopsied as soon as possible; despite the fact that testicular relapse is associated with subclinical disease elsewhere isolated relapse with no obvious bone marrow infiltration remains curable by conventional treatment. Central nervous system relapse at this stage is rare, but should be suspected in the event of the symptoms mentioned previously. The only other site occurring with any frequency is relapse in the iris which presents with apparent iridocyclitis; responding temporarily to steroids and confirmed on biopsy of the iris or examination for leukaemic cells in the anterior chamber.
Planning for long term follow up Maintaining the medical records of all children with chronic disease is a challenge and leukaemia is no exception. A useful exercise at the time of stopping treatment, and one which saves trouble later, is preparation of a treatment summary documenting the protocol, doses, and scheduling of drugs and noting potential late effects. The summary can also give guidance for follow up: for example monitoring with echocardiography after anthracyclines, emphasis on checking growth and puberty after cranial irradiation. It is obviously important to explain this to patients and parents at an appropriate time. Once the child is past the time of maximum risk of relapse, the challenge is to maintain sensitive and appropriate follow up while ensuring that they do not feel a perpetual patient. 
